Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

Launched by BETTINA MITTENDORFER · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how certain cells in the fat tissue, called macrophages, behave in people with obesity and related health issues like diabetes and fatty liver disease. The researchers want to understand how these cells process fats and sugars differently in people who are obese compared to those who are lean and healthy. By looking at these differences, they hope to find new ways to help people manage obesity and its related conditions.

To be eligible for this trial, participants should be between 18 and 70 years old, not pregnant or breastfeeding, and generally healthy without severe organ issues. There are specific weight and health criteria for different groups, such as those with normal weight, those with obesity but no related health problems, and those with obesity and diabetes. Participants can expect to undergo various tests, including body scans and tissue samples, and those with obesity will also receive support to lose weight. This study is currently recruiting participants of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria :
• • age: ≥18 but ≤70 years
• • not pregnant or breastfeeding
• • weight stable and sedentary before enrollment
• • no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity \[MAO\]-Type 2 Diabetes group)
• • no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)
• * participants must fulfil all of the following group-specific inclusion criteria below:
• Lean group:
• • Body mass index (BMI) ≥18.5 but \<25.0 kg/m2
• • Intrahepatic triglyceride (IHTG) content \<5%
• • fasting blood glucose concentration: \<100 mg/dl
• • blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl
• • Hemoglobin A1C (HbA1c) \<5.7 %
• Metabolically normal obesity (MNO) group:
• • BMI ≥30.0 but \<45.0 kg/m2
• • IHTG content \<5%
• • fasting blood glucose concentration: \<100 mg/dl
• • blood glucose concentration 2 h after a 75 g oral glucose challenge: \<140 mg/dl
• • HbA1c \<5.7 %
• Metabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:
• • BMI ≥30.0 but \<45.0 kg/m2
• • IHTG content \>7.5%
• • fasting blood glucose concentration: ≥100 but \<126 mg/dl
• • blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but \<200 mg/dl
• • HbA1c: ≥5.7 but \<6.4 %
• MAO-type 2 diabetes group:
• • BMI ≥30.0 but \<45.0 kg/m2
• • clinical diagnosis of type 2 diabetes or fasting blood glucose concentration \>126 mg/dl or blood glucose concentration 2 h after a 75 g oral glucose challenge\>200 mg/dl or HbA1c \>6.4 % without medication if not diagnosed and medically treated for diabetes
• Exclusion Criteria:
• • - Individuals that do not meet all inclusion Criterion